EN DE
Watch TuHURA Biosciences, Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

TuHURA Biosciences, Inc (HURA) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of TuHURA Biosciences, Inc stock $1.11, price $1.51, that is 26.5% below the price, quality 24 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

TB TuHURA Biosciences, Inc logo Thin data Nov 10, 2026

TuHURA Biosciences, Inc

HURA · US
Expensive, weak quality

Our calculation puts a fair price 26% below what the stock costs today.

Mixed vs. peers (3/6)
Fair value $1.11 · Overvalued
Quality 24/100
Negative free cash flow
Narrow moat 8/100 · thin data
Thin data
Estimate
Watch TuHURA Biosciences, Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$2,748 $0.4400 Fair Value $1.11 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $0.4400 – $2,748 · fair‑value band $0.8400 – $1.39 · the $1.51 price screens above the $1.11 fair value. As of Nov 10, 2026.

Follow TuHURA Biosciences in your weekly email

Every Wednesday you see whether TuHURA Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.

Show moreShow less

It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-functional and bi-specific antibody-drug conjugates targeting Myeloid Derived Suppressor Cells.

In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers.

The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.

Stock analysis

TuHURA Biosciences, Inc (HURA) currently trades at $1.51, while our estimate is $1.11, 26% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.8400 (bear) to $1.39 (bull), the price of $1.51 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 24/100 (below-average quality), in the Healthcare sector.

TuHURA Biosciences, Inc reported revenue of $0 in FY2026 versus $0 in FY2022. Reported net income was −$30.1M in FY2026.

Key figures

Market cap $95.0M Micro · EPS (TTM) $−0.5000 · Return on equity −161% · Return on assets (EBIT) −170% (5-year average) · Free cash flow −$27.7M · Net cash $2.9M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 52% below its 52-week high and 243% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −26%, HURA screens richer than that median.

Fair Value

Bear $0.8400 Fair Value $1.11 Bull $1.39
Price $1.51 · Downside -26.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 24/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 44
Are margins and returns getting better?
Cashflow 28
Do the profits arrive as real cash?
Financial strength 61
Debt, balance sheet and risk of trouble
Investment 2
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 6
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 20
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Plus one other filing such as a grant, option exercise or tax withholding. It is not a market purchase or sale.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

HURA screens overvalued: fair value 26% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare TuHURA Biosciences, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 3/5 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 24 · Bottom 25%
Fair Value upside −26.5% · Above median
Profitability
Return on assets −109.9% · Bottom 25%
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 4.54× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs HURA
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs HURA
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs HURA
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs HURA
argenx SE ARGX $971.55 $908.40 −7% vs HURA
CSL Limited CSL A$201.68 A$181.40 −10% vs HURA
Moderna, Inc MRNA $250.83 $158.70 −37% vs HURA
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs HURA
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs HURA
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs HURA

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

TuHURA Biosciences, Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "TuHURA Biosciences, Inc Fair Value". https://www.fairvalue-calculator.com/stock/HURA

Frequently asked questions

Is TuHURA Biosciences, Inc (HURA) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $1.11 versus a price of $1.51, about 26% lower (overvalued).
What is the fair value of HURA?
Our estimate for TuHURA Biosciences, Inc is $1.11 (as of Nov 10, 2026), built from audited fundamentals. The current price: $1.51.
What is the quality score of HURA?
TuHURA Biosciences, Inc has a Quality Score of 24/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for TuHURA Biosciences, Inc (HURA)?
Our calculated price target is the estimate of $1.11 (as of Nov 10, 2026). Cautious scenario $0.8400, optimistic scenario $1.39. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the TuHURA Biosciences, Inc stock forecast for 2026?
Our estimate puts fair value at $1.11, about 26% lower versus a price of $1.51 (overvalued). Cautious scenario $0.8400, optimistic scenario $1.39. The calculation is refreshed regularly with new filings.
What is the intrinsic value of TuHURA Biosciences, Inc (HURA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For TuHURA Biosciences, Inc it is $1.11 per share (as of Nov 10, 2026), against a price of $1.51.
Is TuHURA Biosciences, Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, HURA trades above its calculated fair value: price $1.51, fair value $1.11, a gap of about −26% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HURA?
No. The price is what the market pays today ($1.51); the fair value is what the company's own numbers justify ($1.11). For TuHURA Biosciences, Inc the two are $0.4000 per share apart. That gap is exactly why we show both numbers side by side.
How much is TuHURA Biosciences, Inc worth?
The market values TuHURA Biosciences, Inc at about $95.0M (market capitalisation, as of Nov 10, 2026). Per share that is $1.51; our models calculate a fair value of $1.11 per share.
What do the bullish and bearish scenarios say about HURA?
Our models span a range for TuHURA Biosciences, Inc: cautious scenario $0.8400, base $1.11, optimistic $1.39 per share (as of Nov 10, 2026, price $1.51). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of TuHURA Biosciences, Inc (HURA)?
Balance-sheet figures for TuHURA Biosciences, Inc (as of Nov 10, 2026): return on equity −161.4%. They feed the Quality Score of 24/100, which measures business quality independently of the share price.
How far is HURA from its 52-week high?
TuHURA Biosciences, Inc trades at $1.51, about 52% below its 52-week high of $3.15 and 243% above the low of $0.4400 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $1.11 is for.
Which stocks are comparable to TuHURA Biosciences, Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is TuHURA Biosciences, Inc stock attractive at the current price?
The data as of Nov 10, 2026: price $1.51, calculated fair value $1.11 (−26%), Quality Score 24/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. TuHURA Biosciences, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of TuHURA Biosciences, Inc (HURA)?
The closing price on Nov 10, 2026 was $1.51. Our estimate is $1.11, about 26% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with TuHURA Biosciences, Inc right now?
The price sits above even our optimistic bull case ($1.39). The favourable scenario is already priced in. Weak quality (24/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of TuHURA Biosciences, Inc

How large is the market capitalisation of TuHURA Biosciences, Inc (HURA)?
The market capitalisation of TuHURA Biosciences, Inc is $95.0M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of TuHURA Biosciences, Inc (HURA)?
Earnings per share at TuHURA Biosciences, Inc are $−0.5000. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of TuHURA Biosciences, Inc (HURA)?
The return on equity (ROE) of TuHURA Biosciences, Inc is −161% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of TuHURA Biosciences, Inc (HURA)?
On an EBIT basis the return on assets of TuHURA Biosciences, Inc is −170% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does TuHURA Biosciences, Inc (HURA) generate?
The free cash flow of TuHURA Biosciences, Inc is −$27.7M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does TuHURA Biosciences, Inc (HURA) hold?
TuHURA Biosciences, Inc holds more cash than debt, $2.9M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch TuHURA Biosciences, Inc in the live analysis

One click puts TuHURA Biosciences, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.